CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Summary

This study was a one-arm, single-center, phase II clinical study. Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days a treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.

Timeline

Start

2019-04-02

Primary completion

2021-02

Completion

2021-09

Drugs

Indications